![](http://www.biospectrumindia.com/images/content/2010/apr/Nano_biotech.jpg)
From enabling the delivery of engineered drugs to
specific target tissues to multiple possibilities in stem cell
research, nanobiotechnology is certainly the key to the future.
Several researches in nanobiotechnology are going on
in various research institutes, but the lack of efforts in conversion
of basic research to product development, remains the hurdle in India.
“I think, we are still in infancy. Though nanocoated anti-cancer drugs
like Doxil have been in clinical application in the US, we have not
heard of any such breakthrough from India in the drug discovery field,�
says Dr Samuel JK Abraham, director, Niche-in Center for Regenerative
Medicine (NCRM), Chennai.
Dr Anita Goel, CEO, Nanobiosym, says, “Medicine and nanomaterials may
provide some of the first low hanging
commercial fruits from nanotechnology. In medicine, for example,
nanotechnology is enabling novel diagnostic as well as new approaches
to therapy and drug delivery. In nanomedical diagnostics, I envision
the impact of this technology to be somewhat similar to the cell phone
industry. We saw a paradigm shift in the telecom industry when
computing and communications devices became portable. Likewise, I
believe that we will see a similar shift in healthcare when the ability
to detect and diagnose disease can be taken out of pathological labs
and put in the hands of doctors, nurses, and healthcare workers. Well,
at least this is the motivation and vision behind our GeneRadar
technology platform.�
Another major impediment to the sector comes from the long wait for the
regulatory approvals. Therefore, the clear set of guidelines and
regulator is required for this particular sector. Dr Jitendra N Verma,
MD, Life Care Innovations, Gurgaon, says, “I really don't see much
progress in the nanobiotech sector as far as commercialization is
concerned. The conventional approach often leads to the hampering of
approvals and sometimes the opinions may also be misguided. Eventually,
this leads to the patent life being eaten up. The regulatory committees
should understand this.� But, despite having a humble beginning, this
technology is expected to replace the existing technology in a big way.
Dr VK Tripathi, CEO, Virtus Technoinnovations, Mumbai, terms the
nanobiotechnology as 'disruptive technology'. While citing reasons for
using that term, he says, “This is a very powerful technology that will
revolutionize the entire industry, but, at the same time, it will upset
the entire Rs 11.26 lakh crore ($250 billion) spa industry because of
the cost-effectiveness that comes with it. It will certainly lead to
replacing of the conventional methods by more effective ones.�
Recent trends in research
The researchers have exploited the unique properties of nanomaterials
for various applications including cell imaging and therapeutics for
treating cancer. The size of nanomaterials is similar to that of most
biological molecules and structures; therefore, it is used for both
in-vivo and in-vitro biomedical research and applications.
The research by scientists at the Banaras Hindu University and the
India International Advanced Research Center for Powder Metallurgy and
New Materials has shown that silver nanoparticles show 'immense
potential' in the prevention of blood clots. The scientists consider
their discovery as an alternative to aspirin and other anti-platelet
agents currently used to prevent blood clots in coronary artery
disease, heart attack and stroke that often cause dangerous bleeding.
Nanosilver appears to possess dual significant properties of being
antibacterial and antiplatelet, with unique utilities.
Virtus Technoinnovations has developed a patented technology on Gene
Repair Therapy (GRT) to stimulate dormant genes in an attempt to cure
diseases like cancer and AIDS. The company is the first in India to
develop a resveratrol formulation having a half life of three hours,
slow release from intestine and non-trace amounts of upto 53nmols/L.
“In one case we got even 40,000nmols/L of free resveratrol. Our
formulation is a plant produce neither synthetic nor a plant extract
and is free of heavy metals. We hence got a FDA manufacturing license
as a nutrient product. Our excitement really rose because amongst large
number of proven benefits of free resveratrol, one was that free
resveratrol was toxic to cancer cells and protective to healthy cells
during in-vitro and in-vivo animal studies.�
NCRM has successfully accomplished the in-vitro expansion of
hematopoietic stem cells of human origin and from primates using such
scaffolds. In the near future nanosurface coated human autologous
fibroblast culture is likely to revolutionize the facial wrinkle
treatment. At the moment conventional method of fibroblast
culture is used to support the facial anti-wrinkle treatment
in Japan which is gaining popularity. NCRM is working on
enhancing the fibroblast culture work by using appropriate
nanobiotechnology.
Another area of potential application will be in dental stem cells. In
animal studies, corneal surface damages have been repaired using dental
stem cells using temperature sensitive nano-coated surfaces.
“NCRM is planning to take this to clinical studies. These proven
applications using our expertise where in three dimensional culture of
corneal limbal stem cells have been accomplished by our team jointly
with Sankara Nethralaya,� clarifies Dr Abraham, Life Care Innovations
is doing pioneering work in developing
nanobiotech products. The company has developed a nano drug for
tuberculosis that is going to have global implications under the
project funded by the Department of Science & Technology (DST),
Government of India.
“The clinical studies have been completed and now we are waiting
for the Drug Controller General of India's approval. The
three formulations have been already approved and the fourth one is
waiting for the approval,� informs Dr Verma.
“These studies were carried out in collaboration with the University of
South Africa, and CSIR in South Africa. What makes this drug unique is
that in comparison to the general DOT program where drug is taken
everyday, it will have to be taken thrice a month only. The results of
phase II clinical trial are awaited by the South African Medical
research institute for the release of the drug in their country,�
adds Dr Verma.
Mumbai-based NanoBio Chemical, which was founded in 2006, focuses
on nanobio applications in textiles and also the customized synthesis
of complex peptides and biochemical solutions.
Biotech company Bharat
Biotech is developing a novel topical oestrogen hormone replacement
therapy and the New Delhi-based Panacea Biotec is working on novel drug
delivery research using mucoadhesive nanoparticles.
DNA is the natural nanoscale material that carries the genetic
information. This quality makes it an obvious choice for the
researchers working in nanobiotechnology. Therefore, a lot of research
is being done in this field by taking the DNA as the base molecule and
the availability of novel techniques simplifies the study process.
There have been many new developments related to nanobiotechnology
applications in the field of diagnostics as well. The Defence Research
and Development Organization (DRDO) has developed diagnostics tools for
TB and typhoid, using nanobiotechnology. Gene-Radar developed by
US-based Nanobiosym, is a mobile phone like device in which a small
drop of
blood, saliva or water is placed. The machine can then display what
disease the person has. It detects signatures of DNA and RNA as well.
The commercialization of Nanoxel, an injectible vial for dispensing the
cancer drug paclitaxel, by Dabur in India and abroad has also opened
doors to various possibilities. Nanoxel is a cremophor-free polymeric
nanoparticle formulation of
Paclitaxel with no hypersensitivity reactions, which allows
administration to patients without pre-medication as is required with
Cremophor paclitaxel.
Revenue support
The funding for nanotechnology applications is largely from DSIR, DST
and DBT. The Nano Science and Technology Initiative (NSTI) by DST in
2001 under the leadership of Prof. CNR Rao allocated Rs 1,000 crore
($250 million) for nanotechnology research from 2007.
Also a Mission on Nano Science and Technology (Nano Mission) was
launched in May 2007, to foster, promote and develop all aspects of
nanoscience and nanotechnology, which have the potential to benefit the
country. Recently in the budget for 2010-11, Indian government has
increased the funds for the Nano Mission from Rs 70 crore to Rs
100 crore.
“At the early stages when you are doing fundamental scientific
research, government can be an ideal investor in promoting the basic
science and technology agenda. As the innovation starts to get closer
to commercialization, then venture capitalists and private equity
players have a unique role to play to commercially scale up a
technology and to capture market share,� opines Dr Goel.
However, the lack of specific allocation of funds for the R&D in
nanobiotechnology sector seems to hamper the growth of this
sector.“There is a need for the allocation of funds separately for
nanobiotechnology and specifically for the product development and
clinical trials. Then only we can see some visible progress in this
field,� suggests Dr Verma.
PPPs and nanobio products
Nanobiosym is planning to set up multi-purpose nanotechnology
innovation parks, the first-of-its-kind in India. Gujarat and Himachal
Pradesh have signed MOUs with the company to establish the
NanobiosymTech Park in India.
While commenting on this Dr Goel says, “For truly game changing
technology platforms, I think the public-private partnership mechanism
is an ideal way to bring disruptive technologies into market. For
example, a developing country would have to spend huge amounts to
develop its healthcare infrastructure to be at par with the developed
world. But, by investing in game changing technology platforms like the
cell phone or our Gene-Radar nanoscale molecular diagnostic platform,
governments can drive technological change and leapfrog their
healthcare delivery capabilities, because they do not have to build out
the same overhead infrastructure that is required by the conventional
technology platforms.�
NCRM has been working on close to 240 different nanomaterials and
technologies in specialties such as ophthalmology (corneal
regeneration), orthopedics (cartilage injury repair), and hematology
(expansion of hematopoietic stem cells). This has been made possible
because it is an Indo-Japan joint venture organization and has an
access to collaborators technological strength in terms of both nano
products and processing methodologies.
“Though we have got two projects funded by the government bodies
through our collaborators; one with Institute of Pathology, Indian
Council of Medical Research, New Delhi, and other with Sri Ramachandra
University, we usually go for such fundings after filing IP rights,�
shares Dr Abraham. “We are also collaborating with public institutes
such as IOP-ICMR,
Anna University-KBC, and Tanuvas. But, the PPP initiative in
India has to be given more emphasis, and it has to be result
oriented as well,� he further adds.
Life Care Innovations has partnership with PGI Chandigarh, Punjab
University and IIT for the development of nanoliposomal drugs. However,
Dr Verma feels the need for more partnerships between the academia and
industry in this particular sector to get enough products in the
market. “The research going on in the academic and research institutes
has not
reached to the manufacturing stage and it gets lost there only due to
lack of coordination between the public and private sector,� observes
Dr Verma.
Mumbai-based company, Nanocutting Edge Technology, has been doing a lot
of innovative projects related to nanobiotechnology, in
partnership with Agharkar Research Institute, Pune. Nanobiotechnolgy is
projected to play a critical role in patient-specific therapy; however,
this transition will depend heavily on the evolutionary development of
a systems biology approach to clinical medicine-based upon technology
analysis and integration.
As Dr Goel says rightly, “There is certainly a lot of buzz out there
about nanotechnology and thus one has the additional burden of proof to
separate fact from fiction and the real applications from the far-off
ones.�
![](http://www.biospectrumindia.com/images/content/2010/apr/Dr_Samuel_JK_Abraham%28Nano_Biotech%29.jpg)
“I think, we are still in infancy. Though nanocoated
anti-cancer drugs like Doxil have been in clinical application in the
US, we have not heard of any such breakthrough from India in drug
discovery field�
- Dr Samuel JK Abraham, director,
NCRM,
Chennai
![](http://www.biospectrumindia.com/images/content/2010/apr/Dr_%20VK_Tripathi%28Nano_Biotech%29.jpg)
“This is a very powerful technology that will
revolutionize the entire industry, but, at the same time, it will upset
the entire spa industry because of the cost-effectiveness that comes
with it. It will certainly lead to replacing of the conventional
methods by more effective ones�
-
Dr VK Tripathi, CEO, Virtus
Technoinnovations, Mumbai
Rahul Koul and Jahanara Parveen